GlassScriptPhysician profile
Ole Saetrum Opgaard
NPI 1649211012
$4,055.17
in general payments reported to CMS, 2019-2025
22 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $103 · 2021: $146 · 2022: $758 · 2023: $1,043 · 2024: $926 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,095.67 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $588.56 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $433.94 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $414.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.67 | 2021-2025 | Jardiance, Tradjenta |
| Insulet Corporation | $247.34 | 2019-2025 | Omnipod |
| Amgen INC. | $154.66 | 2024-2025 | Tepezza |
| Sanofi-Aventis U.S. LLC | $136.29 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.00 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $98.92 | 2023-2025 | Baqsimi |
| Astrazeneca Pharmaceuticals LP | $82.73 | 2022-2023 | Farxiga |
| Mannkind Corporation | $79.49 | 2019 | |
| Ascendis Pharma Endocrinology INC | $73.71 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $71.95 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $56.71 | 2019-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $42.63 | 2022-2025 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $21.50 | 2025 | Isturisa |
| Sequel Med Tech, LLC | $21.48 | 2025 | Twiist |
| Ibsa Pharma INC. | $17.75 | 2023 | Tirosint, Licart |
| Medtronic, INC. | $17.52 | 2021 | |
| Becton, Dickinson and Company | $15.64 | 2022 | |
| Halozyme INC | $14.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ole Saetrum Opgaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.